Revenue grew 10% year-over-year in Q3 2025, with positive operating profit and strong customer demand. A rights issue was approved to fund growth and repay loans, while strategic partnerships and clinical studies support long-term expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.